Literature DB >> 34722722

Obesity and Gallstones.

Nela Melissa Parra-Landazury1, Jacqueline Cordova-Gallardo2,3, Nahum Méndez-Sánchez3,4.   

Abstract

BACKGROUND: The prevalence of obesity has been increasing globally and represents the main risk factor for the development of gallstone disease (GD).
SUMMARY: Excess body weight represents the main cause for the development of GD; nevertheless, there have been described multiple risk factors for its development, among them modifiable risk factors as diet, lifestyle, physical inactivity, and non-modifiable risk factors as ethnicity, female sex, advanced age, parity, and genetic mutations. Body mass index, abdominal perimeter, and waist-hip index have been used to determine the degree of adiposity of a person. Hence, central abdominal fat has been mostly associated with insulin resistance with the consequent increase in the hepatic cholesterol secretion; contributing as one of the multiple mechanisms associated with the development of gallstones. This disease has a low mortality; however, it has been associated with multiple diseases such as cardiovascular diseases, carotid atherosclerosis, metabolic associated fatty liver disease, and gallbladder cancer, probably because they share many of the risk factors. KEY MESSAGES: GD continues to be considered a disease with a high medical burden, in which it is sought to intervene in modifiable risk factors to reduce its development.
Copyright © 2021 by S. Karger AG, Basel.

Entities:  

Keywords:  Bile acids; Biliary lipids; Cholecystokinin; Gallstones; Nuclear receptors

Year:  2021        PMID: 34722722      PMCID: PMC8543292          DOI: 10.1159/000515545

Source DB:  PubMed          Journal:  Visc Med        ISSN: 2297-4725


  79 in total

1.  Gallstone disease is associated with increased mortality in the United States.

Authors:  Constance E Ruhl; James E Everhart
Journal:  Gastroenterology       Date:  2010-11-11       Impact factor: 22.682

Review 2.  Roles of FGF19 in liver metabolism.

Authors:  S Kir; S A Kliewer; D J Mangelsdorf
Journal:  Cold Spring Harb Symp Quant Biol       Date:  2011-08-03

3.  Cholelithiasis and markers of nonalcoholic fatty liver disease in patients with metabolic risk factors.

Authors:  Tomas Koller; Jana Kollerova; Tibor Hlavaty; Martin Huorka; Juraj Payer
Journal:  Scand J Gastroenterol       Date:  2011-12-19       Impact factor: 2.423

Review 4.  Pathophysiological connections between gallstone disease, insulin resistance, and obesity.

Authors:  Víctor A Cortés; Francisco Barrera; Flavio Nervi
Journal:  Obes Rev       Date:  2019-12-08       Impact factor: 9.213

5.  Strong association between gallstones and cardiovascular disease.

Authors:  Nahum Méndez-Sánchez; Jesús Bahena-Aponte; Norberto C Chávez-Tapia; Daniel Motola-Kuba; Karla Sánchez-Lara; Guadalupe Ponciano-Radríguez; Martha H Ramos; Misael Uribe
Journal:  Am J Gastroenterol       Date:  2005-04       Impact factor: 10.864

6.  Statin use and risk of gallstone disease followed by cholecystectomy.

Authors:  Michael Bodmer; Yolanda B Brauchli; Stephan Krähenbühl; Susan S Jick; Christoph R Meier
Journal:  JAMA       Date:  2009-11-11       Impact factor: 56.272

Review 7.  Biliary lipids and cholesterol gallstone disease.

Authors:  David Q-H Wang; David E Cohen; Martin C Carey
Journal:  J Lipid Res       Date:  2008-11-17       Impact factor: 5.922

8.  Prospective study of abdominal adiposity and gallstone disease in US men.

Authors:  Chung-Jyi Tsai; Michael F Leitzmann; Walter C Willett; Edward L Giovannucci
Journal:  Am J Clin Nutr       Date:  2004-07       Impact factor: 7.045

Review 9.  Transcriptional regulation of hepatic lipogenesis.

Authors:  Yuhui Wang; Jose Viscarra; Sun-Joong Kim; Hei Sook Sul
Journal:  Nat Rev Mol Cell Biol       Date:  2015-11       Impact factor: 94.444

Review 10.  New Aspects of Lipotoxicity in Nonalcoholic Steatohepatitis.

Authors:  Nahum Mendez-Sanchez; Vania Cesar Cruz-Ramon; Oscar Lenin Ramirez-Perez; Jessica P Hwang; Beatriz Barranco-Fragoso; Jaqueline Cordova-Gallardo
Journal:  Int J Mol Sci       Date:  2018-07-13       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.